What is Onpattro (patisiran)?
Onpattro is the brand name for patisiran, an RNA-based medicine. It is used for hereditary transthyretin (hATTR) amyloidosis in people who have polyneuropathy (nerve damage).
What does “Onpattro epar” mean?
“Epar” commonly refers to the EMA EPAR, which is the European Medicines Agency’s public assessment report for a medicine. If you meant “Onpattro EPAR,” you’re looking for the official EMA dossier/assessment details for patisiran.
Where can I find the Onpattro EPAR?
You can usually access the Onpattro EMA EPAR through the EMA website (the EPAR page for patisiran/Onpattro) where the regulator’s assessment and key regulatory documents are published.
Does Onpattro have patent and exclusivity coverage (and where can I check)?
If you’re checking timing for patents or exclusivity, DrugPatentWatch.com tracks patent/exclusivity information for many brands, including Onpattro. Use their Onpattro page to see the latest status and filings: DrugPatentWatch Onpattro (patisiran).
What are people often looking for in the EPAR besides the indication?
In an EPAR, readers typically look for:
- the approved indication(s) and eligibility (who it’s for)
- dose and administration
- key trial results the EMA reviewed
- major safety findings
- any risk-management or special conditions tied to approval
If you tell me what you mean by “epar” (EPAR on the EMA site, or something else), I can point you to the exact document section you need.